Tango Therapeutics, Inc.
TNGXHealthcareNASDAQBiotechnology · Last scanned Jun 4, 2026
Scan Results
Daily timeframePart of the healthcare sector, Tango Therapeutics, Inc. (TNGX) is listed under Biotechnology. With a market capitalization of $3.11B, it sits in mid-cap territory. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Market Cap
$3.11B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-13.50
EPS (TTM)
$-0.83
EPS (Fwd)
$-1.59
ROE
-38.4%
ROA
-20.7%
Cash
$379.8M
Total Debt
$32.8M
Free CF
-$68.2M
52W Change
512.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $379.8M in cash comfortably exceeding the $32.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$68.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $24.9M (2022) to $62.4M (2025), reflecting a 151% increase over the period.
With cash comfortably exceeding debt, TNGX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TNGX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.